Valganciclovir

Common brands: Valcyte, Valganciclovir Hydrochloride, Prograf, Envarsus Xr, Tacrolimus

Top reporter: H2-Pharma, Llc

Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor [EPC]Corticosteroid [EPC]Calcineurin Inhibitor Immunosuppressant [EPC]Azole Antifungal [EPC]Dihydrofolate Reductase Inhibitor Antibacterial [EPC]
18,446
Total Reports
9,178
Serious Reports
3,190
Death Reports
30
Reported Reactions
Death Report Ratio: High (17.29%)

Patient Demographics

Male
9,594
Female
6,514

Reported Adverse Reactions (30)

Side effects reported in FDA adverse event reports for Valganciclovir.

# Reaction Reports % of Total
1 OFF LABEL USE 2,937
13.2%
2 CYTOMEGALOVIRUS INFECTION 1,795
8.0%
3 DRUG INEFFECTIVE 1,475
6.6%
4 NEUTROPENIA 1,114
5.0%
5 PYREXIA 948
4.2%
6 LEUKOPENIA 932
4.2%
7 DIARRHOEA 927
4.2%
8 ACUTE KIDNEY INJURY 819
3.7%
9 DEATH 758
3.4%
10 CYTOMEGALOVIRUS VIRAEMIA 734
3.3%
11 PANCYTOPENIA 689
3.1%
12 DRUG RESISTANCE 658
2.9%
13 ANAEMIA 647
2.9%
14 TRANSPLANT REJECTION 635
2.8%
15 THROMBOCYTOPENIA 620
2.8%
16 PNEUMONIA 595
2.7%
17 PRODUCT USE IN UNAPPROVED INDICATION 553
2.5%
18 NAUSEA 512
2.3%
19 SEPSIS 504
2.3%
20 CYTOMEGALOVIRUS INFECTION REACTIVATION 483
2.2%
21 RENAL IMPAIRMENT 480
2.2%
22 VOMITING 438
2.0%
23 DRUG INTERACTION 424
1.9%
24 BLOOD CREATININE INCREASED 415
1.9%
25 URINARY TRACT INFECTION 389
1.7%
26 INTENTIONAL PRODUCT USE ISSUE 381
1.7%
27 RENAL FAILURE 374
1.7%
28 SEPTIC SHOCK 362
1.6%
29 FATIGUE 359
1.6%
30 PATHOGEN RESISTANCE 359
1.6%

Important Disclaimer

FDA adverse event reports are submitted voluntarily and do not prove causation. A reported reaction does not mean the drug caused it. Drugs with more users naturally have more reports. Always consult your doctor or pharmacist before making medication decisions.